This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US high court’s ‘skinny label’ decision may not chill market as generics warn

By Nick Robertson ( January 20, 2026, 21:38 GMT | Comment) -- Generic and biosimilar manufacturers and the US Solicitor General have warned that a Supreme Court holding against Hikma Pharmaceuticals could dismantle the generic drug market. But with so-called “skinny labels” affixed to just over two dozen medications on the market, one attorney told MLex that last week’s grant of certiorari is “much ado about nothing.”The US Supreme Court will hear a patent case for the first time in three years, granting certiorari Friday in Hikma Pharmaceuticals’ appeal of findings that it may be held liable for the induced infringement of Amarin Pharma patents in connection with a “skinny label.”...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections